Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 80

Sort by

Sort Order Select

Journal Articles

Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma

Tracy T. Chow, Michael Amatangelo, Peilin Ma, Chad C. Bjorklund, Krista Wollerman, Tiziana Civardi, Phillip Koo, Yue Zhu, Paulo Maciag, Jessica Katz, Aparna Raval, Albert Oriol, Robert Z. Orlowski, Darrell White, Paul G. Richardson, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 3318.

https://doi.org/10.1182/blood-2023-178881

Published: 2023

Journal Articles

Clonal Hematopoiesis-Related Mutations Are Associated with Favorable Clinical Benefit Following Luspatercept Treatment in Patients with Lower-Risk Myelodysplastic Syndromes: A Subgroup Analysis from the Phase 3 COMMANDS Trial

Maroof Hasan, Sadanand Vodala, Sheida Hayati, Guillermo Garcia-Manero, Anita K. Gandhi, Rajasekhar N.V.S. Suragani

Blood (2023) 142 (Supplement 1): 3214.

https://doi.org/10.1182/blood-2023-178666

Published: 2023

Journal Articles

A Multiomic Single-Cell Atlas of Human Myelopoiesis Reveals Cellular and Molecular Drivers of Immunomodulatory Drug-Induced Neutropenia

Christina Simoglou Karali, Simone Riva, Sally-Ann Clark, Sean Wen, Nikolaos Sousos, Eleni Louka, E. Ravza Gür, Nawshad Hayder, William E. Pierceall, Anjan Thakurta, Anita K. Gandhi, Patrick R Hagner, Jim Hughes, Adam J Mead

Blood (2023) 142 (Supplement 1): 935.

https://doi.org/10.1182/blood-2023-182041

Published: 2023

Journal Articles

Tumor Mutational Burden As a Prognostic Factor in Diffuse Large B-Cell Lymphoma

Rosalie Griffin, Kerstin Wenzl, Vivekananda Sarangi, Lisa M. Rimsza, Rebecca King, Andrew L. Feldman, Matthew J. Maurer, Grzegorz S. Nowakowski, Brian K. Link, Thomas M. Habermann, Nicholas Stong, C. Chris Huang, Anita K. Gandhi, Susan L. Slager, Anne J. Novak, James R. Cerhan

Blood (2023) 142 (Supplement 1): 1633.

https://doi.org/10.1182/blood-2023-182291

Published: 2023

Journal Articles

Predictive Biomarkers of Response to Luspatercept in Patients with Myelofibrosis- (MF) Associated Anemia: Biomarker Analysis from the ACE-536-MF-001 Study

Danny Jeyaraju, Sheida Hayati, Niloufar Marsousi, Aaron T. Gerds, Francesco Passamonti, Fabian Sanabria, Sadanand Vodala, Anita K. Gandhi, Rajasekhar N.V.S. Suragani

Blood (2023) 142 (Supplement 1): 6330.

https://doi.org/10.1182/blood-2023-182155

Published: 2023

Journal Articles

Luspatercept Modulates Inflammation in the Bone Marrow, Restores Effective Erythropoiesis/Hematopoiesis, and Provides Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase 3 COMMANDS Study

Sheida Hayati, Amer M. Zeidan, Guillermo Garcia-Manero, Uwe Platzbecker, Aarif Ahsan, Amit K. Verma, Srinivas Aluri, Manuel Ugidos Guerrero, Anita K. Gandhi, Rajasekhar N.V.S. Suragani, Sadanand Vodala

Blood (2023) 142 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2023-178674

Published: 2023

Journal Articles

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Lucia Y Chen, Oliver Van Oekelen, Michael Amatangelo, Tracy T. Chow, Bhaskar Upadhyaya, Alessandro Lagana, Geoffrey Kelly, Seunghee Kim-Schulze, Adolfo Aleman, Antonina Kurtova, Sarah Gooding, Sundar Jagannath, Erin Flynt, Anita K. Gandhi, Udo Oppermann, Anjan Thakurta, Samir Parekh

Blood (2023) 142 (Supplement 1): 4686.

https://doi.org/10.1182/blood-2023-187748

Published: 2023

Journal Articles

Emergence of Highly-Plastic B Cell States Cooperates with Early Immune Microenvironment Remodeling to Drive Follicular Lymphomagenesis

Blood (2023) 142 (Supplement 1): 717.

https://doi.org/10.1182/blood-2023-185829

Published: 2023

Journal Articles

Iberdomide Enhances Dara Mediated Cytotoxicity through Upregulation of CDC Activity and Elevated NK Cell Mediated ADCC

Peilin Ma, Vinidhra Sridharan, Krista Wollerman, Debjani Dutta, Ram Kumar Singh, Sambuddo Mukherjee, Chad C. Bjorklund, Patrick R Hagner, Michael Amatangelo, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 3289.

https://doi.org/10.1182/blood-2023-189423

Published: 2023

Journal Articles

Pharmacodynamic Biomarkers and CtDNA Support the Mechanism of Action and Clinical Efficacy of Golcadomide (CC-99282) Combined with R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma

Mark Kaplan, Tara Basavanhally, Yumi Nakayama, Charalampos Kyriakopoulos, Arnaud Amzallag, Argyrios Gkasiamis, Arpankumar Patel, Akshay Sudhindra, Grzegorz S. Nowakowski, Jason Westin, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 1631.

https://doi.org/10.1182/blood-2023-180231

Published: 2023

Journal Articles

Molecular Classification of Relapsed DLBCL Reveals Novel Biologic Subgroups

Blood (2023) 142 (Supplement 1): 2770.

https://doi.org/10.1182/blood-2023-180949

Published: 2023

Journal Articles

RRMM and Post-BCMA Treated Subjects from the CC-220-MM-001 Study Show Increased Genomic Aberrations Associated with High-Risk and Significant Dysfunction in CD4+ T-Cell Compartment Compared to NDMM Subjects

Michael Amatangelo, Erin Flynt, Nicholas Stong, Maria Ortiz, Pradipta Ray, Maria Wang, Niels W.C.J. van de Donk, Sagar Lonial, Aparna Raval, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 4665.

https://doi.org/10.1182/blood-2023-178912

Published: 2023

Journal Articles

Fedratinib Overcomes Ruxolitinib Resistance through Inhibition of the Interferon Signaling Pathway

Danny Jeyaraju, Ann Polonskaia, Chih-Chao Hsu, Patrick R Hagner, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 1434.

https://doi.org/10.1182/blood-2023-181898

Published: 2023

Journal Articles

An Integrated Single Cell Immunogenomic Atlas Reveals Pathways of Clonal Expansion, Inflammation and Dyserythropoiesis in Low and High-Risk Clonal Haematopoiesis

Xuesen Zheng, Amandine Tan, Maria del Pilar Casares Alaez, Garry Mallett, Deniz Ece Kaya, Nogayhan Seymen, Marta Rzepkowska, Sarah Mackie, Prodromos Chatzikyriakou, Laarni Bogaanay, Jen Lewis, Maroof Hasan, Rajasekhar N.V.S. Suragani, James Carmichael, Ghulam Mufti, Anita K. Gandhi, Giorgio Napolitani, Lynn Quek

Blood (2023) 142 (Supplement 1): 812.

https://doi.org/10.1182/blood-2023-174947

Published: 2023

Journal Articles

Differential Chromatin Organization between t(4;14) and Non-t(4;14) Multiple Myeloma Driven By the Histone Methyltransferase NSD2

Chad C. Bjorklund, Junfei Zhao, Gaurav Jain, Natasha Shtraizent, Maria Ortiz, Sambuddo Mukherjee, Patrick R Hagner, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 3295.

https://doi.org/10.1182/blood-2023-190137

Published: 2023

Journal Articles

Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker Analysis from the Phase 3 FREEDOM2 Trial

Danny Jeyaraju, Sheida Hayati, Jia Wang, Claire N Harrison, Jean-Jacques Kiladjian, Christopher Hernandez, Patrick Brown, Daniel Lopes De Menezes, Anita K. Gandhi, Rajasekhar N.V.S. Suragani

Blood (2023) 142 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2023-180419

Published: 2023

Journal Articles

A Single Cell Atlas of Diffuse Large B Cell Lymphomas Reveals Distinct Cellular States Predictive of Outcomes

Blood (2023) 142 (Supplement 1): 848.

https://doi.org/10.1182/blood-2023-173929

Published: 2023

Journal Articles

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Daniel Lopes De Menezes, Manuel Ugidos Guerrero, Arnaud Amzallag, Wendy L. See, Alberto Risueno, Charalampos Kyriakopoulos, Rajasekhar N.V.S. Suragani, Barry S. Skikne, C.L. Beach, Thomas Prebet, Maria Teresa Voso, Andre C. Schuh, Gail J. Roboz, Hartmut Döhner, Andrew H. Wei, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 1582.

https://doi.org/10.1182/blood-2023-187651

Published: 2023

Journal Articles

Mezigdomide Reverses T-Cell Exhaustion through Degradation of Aiolos/Ikaros and Reinvigoration of Cytokine Production Pathways

Hsiling Chiu, Junfei Zhao, Maria Ortiz Estevez, Patrick R Hagner, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 335.

https://doi.org/10.1182/blood-2023-189445

Published: 2023

Journal Articles

Celmod Induced Disruption of Granulopoiesis Continuum Identified Using Humanized Cereblon Mice

Ajit Dhadve, Neelam Kumari, Amrutha Y, Riddhita Deb, Gobinathan Rengarasu, Ramya V, Swetha Muralidhar, Shwetank Verma, Patrick R Hagner, Sambuddo Mukherjee, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 5586.

https://doi.org/10.1182/blood-2023-189539

Published: 2023

NARROW

Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma

Clonal Hematopoiesis-Related Mutations Are Associated with Favorable Clinical Benefit Following Luspatercept Treatment in Patients with Lower-Risk Myelodysplastic Syndromes: A Subgroup Analysis from the Phase 3 COMMANDS Trial

A Multiomic Single-Cell Atlas of Human Myelopoiesis Reveals Cellular and Molecular Drivers of Immunomodulatory Drug-Induced Neutropenia

Tumor Mutational Burden As a Prognostic Factor in Diffuse Large B-Cell Lymphoma

Predictive Biomarkers of Response to Luspatercept in Patients with Myelofibrosis- (MF) Associated Anemia: Biomarker Analysis from the ACE-536-MF-001 Study

Luspatercept Modulates Inflammation in the Bone Marrow, Restores Effective Erythropoiesis/Hematopoiesis, and Provides Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase 3 COMMANDS Study

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Emergence of Highly-Plastic B Cell States Cooperates with Early Immune Microenvironment Remodeling to Drive Follicular Lymphomagenesis

Iberdomide Enhances Dara Mediated Cytotoxicity through Upregulation of CDC Activity and Elevated NK Cell Mediated ADCC

Pharmacodynamic Biomarkers and CtDNA Support the Mechanism of Action and Clinical Efficacy of Golcadomide (CC-99282) Combined with R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma

Molecular Classification of Relapsed DLBCL Reveals Novel Biologic Subgroups

RRMM and Post-BCMA Treated Subjects from the CC-220-MM-001 Study Show Increased Genomic Aberrations Associated with High-Risk and Significant Dysfunction in CD4+ T-Cell Compartment Compared to NDMM Subjects

Fedratinib Overcomes Ruxolitinib Resistance through Inhibition of the Interferon Signaling Pathway

An Integrated Single Cell Immunogenomic Atlas Reveals Pathways of Clonal Expansion, Inflammation and Dyserythropoiesis in Low and High-Risk Clonal Haematopoiesis

Differential Chromatin Organization between t(4;14) and Non-t(4;14) Multiple Myeloma Driven By the Histone Methyltransferase NSD2

Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker Analysis from the Phase 3 FREEDOM2 Trial

A Single Cell Atlas of Diffuse Large B Cell Lymphomas Reveals Distinct Cellular States Predictive of Outcomes

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Mezigdomide Reverses T-Cell Exhaustion through Degradation of Aiolos/Ikaros and Reinvigoration of Cytokine Production Pathways

Celmod Induced Disruption of Granulopoiesis Continuum Identified Using Humanized Cereblon Mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only